Cannabis Science Inc. - CLINICAL DRUG DEVELOPMENT

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth
Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements
Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions
Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally
Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations